ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has appointed a project manager to lead the preclinical development of its in-licensed triple negative breast cancer treatment, CLX001. Zai Ahmad has over 20 years’ experience in oncology, neuroscience, and drug development and joins the ValiRx team from Oxford Biomedica, where she was principal scientist and product research and development team lead. Zai has previously held roles at Covance, AstraZeneca, The Institute of Cancer Research, the University of Leeds, the University of Oxford,…

Read the latest People Pathways newsletter for your monthly round up of employee engagement activities.

PRESS RELEASE PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical Oxford, UK – 14th December 2022 – PrecisionLife Limited (“PrecisionLife”), a global techbio company generating the deepest insights into disease biology to create novel precision medicines in chronic diseases today announced that it has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. (“Ono”), an R&D-orientated pharmaceutical company. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated…

Scott Maidment appointed as Head of HTS to lead the new service Expanded facilities gives Company total of 20,160 sq. ft at Granta Park, Cambridge, UK   Cambridge, UK, 30 November 2022: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the launch of its High Throughput Screening (HTS) capability, as well as the expansion of its state-of-the-art lab and office facilities. Scott Maidment has been appointed as Head of HTS to lead the new service. The Company has signed a nine-year lease for an additional 8,…

Research targeted at identifying novel inhibitors or activators of Kv3.1 mutation Cambridge, UK, and Toronto, Canada, 07 December 2022: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra rare genetic disorder, today announced a collaboration to progress a hit identification research project for small molecule modulators of the potassium ion channel Kv3.1, targeting KCNC1-related disorders. Variants of the KCNC1 gene…

Have you noticed how the topic on everyone’s lips in the world of work has shifted from ‘how do we make hybrid working work?’ to ‘how do we engage and retain our staff?’    Here at ML&C HQ we’ve been reflecting on the amazing year we’ve had (so far!) with all our lovely clients, and in particular on some of the conversations we’ve had, some of the bespoke projects we’ve been privileged to work on, and all the talented and motivated participants we’ve got to know in the process.   It’s with this backdrop that we’re launching our winter campaign to introduce you to our…

AMSBIO offers a wide range of small molecules to provide scientists with targeted tools to direct cell fates, making them crucial in areas including regenerative medicine and cancer research.  Small molecules are cell-permeable organic compounds with low molecular weights, which are chemically produced, in contrast to larger molecules such as proteins which are often produced via biological means. Small molecules are crucial components of an affordable cell culture toolkit that can be used to maintain, reprogram, and differentiate cells. Typically, small molecules are cost-effective:…

Capivasertib alongside hormone therapy doubles time before advanced breast cancer progresses  Combination set to become new treatment option for patients with advanced forms of most common type of breast cancer  Inhibitor of cancer-driving protein AKT shows broad benefits in patients with ER positive, HER2 negative breast cancer A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people…

Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant GPCR targets for structure-based drug design Tokyo, Japan and Cambridge, UK, 8 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces it has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the…

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces a selection of new contract wins where Optimer technology is being explored by partners to offer new strategies for therapeutics and potentially offer improved assay sensitivity and selectivity over antibodies. Optimer binders are oligonucleotide-based affinity ligands generated through the in vitro Optimer platform, which can be used as antibody alternatives. They offer benefits of ethical compliance with no use of animals in discovery, development of manufacture, the…